Anti-Fibrinolytic Drugs - Kazakhstan

Kazakhstan

In Kazakhstan, the revenue in the Anti-Fibrinolytic Drugs market is projected to reach US$7.19m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 5.10%, resulting in a market volume of US$9.22m by 2029.
When compared globally, United States is expected to generate the highest revenue of US$9,858.00m in 2024.
Kazakhstan's growing pharmaceutical industry is witnessing an increased demand for anti-fibrinolytic drugs, driven by the rising prevalence of cardiovascular diseases in the country.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Fibrinolytic Drugs market in Kazakhstan has been experiencing significant growth in recent years.

Customer preferences: Kazakhstan's population is aging, and as a result, there has been an increase in the number of patients suffering from cardiovascular diseases. This has created a growing demand for Anti-Fibrinolytic Drugs, which are used to treat these conditions. Additionally, the country's healthcare system has been improving, providing better access to drugs for patients.

Trends in the market: The Anti-Fibrinolytic Drugs market in Kazakhstan is expected to continue growing in the coming years. The government has increased its spending on healthcare, which has led to an increase in the number of hospitals and clinics. This, in turn, has created a greater demand for drugs, including Anti-Fibrinolytic Drugs. Additionally, there has been a rise in medical tourism in Kazakhstan, which has further boosted the demand for these drugs.

Local special circumstances: Kazakhstan has a large population of ethnic Russians, who have a higher incidence of cardiovascular diseases. As a result, there is a higher demand for Anti-Fibrinolytic Drugs in regions with a high concentration of ethnic Russians. Additionally, the country's geography and climate can make it difficult to transport drugs to certain regions, which can lead to supply chain issues.

Underlying macroeconomic factors: Kazakhstan's economy has been growing steadily in recent years, which has led to an increase in disposable income. This has allowed more people to afford healthcare, including Anti-Fibrinolytic Drugs. Additionally, the government has been investing heavily in infrastructure, which has led to an increase in the number of hospitals and clinics. This has created a greater demand for drugs, including Anti-Fibrinolytic Drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.